Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov page footer now displays site revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check12 days agoChange DetectedThe ClinicalTrials.gov record for this Phase 2 small cell lung cancer study is now available, showing that the study is completed and no longer recruiting, along with its treatment arms, eligibility criteria, measured outcomes, and participating locations.SummaryDifference100%

- Check19 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0. The study record page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedA sitewide NIH notice about using “Super Intelligence” in place of “Artificial Intelligence” appears above the page, which still displays a 403 error. The site revision label changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe site’s footer revision changed from v3.7.0 to v3.7.1, and a feedback tab is visible along the page edge.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study record page now displays a 403 Forbidden error page with a Home link, replacing the usual content and preventing access to the trial's details. This change removes the expected study information from the page and directs users to the site’s home page instead.SummaryDifference22%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.